A Phase 1/2 interventional study of NB-4746 High dose and NB-4746 Low dose in Amyotrophic Lateral Sclerosis (ALS), sponsored by Nura Bio. Recruiting at 12 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Nura Bio · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia — 8 open to participants now, 13 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Australia.
Among the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, this one is the 20th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 7 of the 12 other live ones, and was the 43rd registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →8 of the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia are open now. Recruiting first, the newest first:
Celosia Therapeutics Pty Ltd · Sites in Australia
Ages 18–80
Zydus Therapeutics Inc. · Sites in Australia, United States, Belgium and 9 more countries
Ages 18+
Mario Negri Institute for Pharmacological Research · Sites in Australia, Italy
Ages 18+
Regeneron Pharmaceuticals · Sites in Australia, Belgium, Canada and 6 more countries
Ages 18+
The Florey Institute of Neuroscience and Mental Health · Sites in Australia
Ages 18–85
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 22 · Phase 3 15 · Phase 4 1
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 63 across the 44 interventional studies. Of the 24 that completed or were terminated, 14 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 44 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Nura Bio as lead sponsor.
Nura Bio has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Amyotrophic Lateral Sclerosis with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06126315Phase 3Mario Negri Institute for Pharmacological ResearchTrial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS | 2027-04 |
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07369076Nura BioA Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. | 2027-04 |
Add all 3 to your calendar (.ics) → With an account.
Among the 44 studies in Amyotrophic Lateral Sclerosis with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to learn about the effects of NB-4746 compared with placebo in people with amyotrophic lateral sclerosis.
The questions this trial aims to answer in comparing NB-4746 to placebo are:
This trial has 2 parts. The trial doctors will start Part A before starting Part B of the trial. Participants have an option to enter the open label extension after completing Part A or Part B.
Part A: Participants will be randomly placed into 1 of the 3 groups. There are equal chances to be assigned to either group. Group 1: Participants will receive NB-4746 capsules at a low dose to take by mouth twice daily for 1 month. Group 2: Participants will receive NB-4746 capsules at a high dose to take by mouth twice daily for 1 month. Group 3: Participants will receive placebo capsules to take twice daily for approximately 1 month.
Part B: Participants will be randomly placed into 1 of the 2 groups. There are equal chances to be assigned to either group. Group 1: Participants will receive NB-4746 capsules at a dose determined by Part A to take by mouth twice daily for 12 weeks. Group 2: Participants will receive placebo capsules to take twice daily for approximately 12 weeks.
None of the participants, trial doctors, or trial staff will know which treatment the participants will receive during Part A or B. Some trials are done this way because knowing what treatment the participants receive can affect the results of the trial. Doing a trial this way helps to make sure that the results are looked at with fairness across all treatments.
Open-Label Extension: Upon the completion of Part A or Part B, the doctor will verify the participant's willingness to continue receiving study treatment. This open label extension continues until each participant completes up to 1 year of treatment. The trial doctors will check participants' ALS and general health throughout the trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- ALS Criteria for Phase 1b:
Participants in Phase 1b must have:
Symptom onset ≤48 months prior to randomization on Day 1. Date of first ALS symptom (any ALS symptom) onset is defined as the onset of weakness in the limbs, bulbar region, or trunk. Weakness in the bulbar region includes dysarthria and dysphagia.
Participants in Phase 2 must have:
Symptom onset ≤24 months prior to randomization on Day 1. Date of first ALS symptom (any ALS symptom) onset is defined as the onset of weakness in the limbs, bulbar region, or trunk. Weakness in the bulbar region includes dysarthria and dysphagia.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive two NB-4746 capsules (high dose), BID
Drug: NB-4746 High dose
Participants will receive two NB-4746 capsules (low dose), BID
Drug: NB-4746 Low dose
Participants will receive two capsules of placebo per dose, BID.
Drug: Placebo
Participants will receive two capsules of NB-4746 (dose selected after review of Ph 1b data), BID
Drug: NB-4746 (Dose TBD)
Participants will receive two capsules of placebo, BID
Drug: Placebo
NB-4746 will be administered twice daily in 2 capsules (high dose)
NB-4746 will be administered twice daily in 2 capsules (low dose)
Two capsules of placebo will be administered twice daily.
Two capsules of NB-4746 will be administered twice daily (dose will be defined after Ph 1b data is reviewed).
Ph 1b - Number of TEAEs and SAEs
Number of treatment emergent adverse events (TEAEs) and number of serious adverse events (SAEs). This will be assessed in the Ph 1b part of the study.
Time frame: From enrollment to 28 days
Evaluate safety and tolerability of NB-4746 in adult participants with ALS.
Incidence of treatment emergent adverse events (TEAEs) and abnormalities in vital signs, clinical laboratory assessments, and electrocardiograms (ECGs). This will be assessed in the Ph 2 part of the study
Time frame: From enrollment to Week 12
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.
Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →